Subscribe

DOI: 10.4244/EIJV9I1A24

“First-in-man” use of bioresorbable vascular scaffold in saphenous vein graft

Paul Jau Lueng Ong, MD, FESC; Fahim Haider Jafary, MD, FACC; Hee Hwa Ho*, MD, FACC

A 52-year-old male underwent coronary angiography for non-ST-elevation myocardial infarction. He had a known history of diabetes mellitus and also triple vessel disease with prior coronary artery bypass grafting (CABG) six years ago. Angiography showed total occlusion of the left anterior descending (LAD), circumflex and right coronary arteries (RCA). Left internal mammary graft to LAD was patent. However, there were two critical stenoses in the mid-body of the SVG-RCA and SVG-obtuse marginal (OM) grafts (Figure 1A and Figure 1B). We proceeded to perform percutaneous coronary intervention of both lesions with the prophylactic use of an embolic protection device. After predilation of both lesions, an Absorb™ bioresorbable vascular scaffold 3.0×18 mm (Abbott Vascular, Santa Clara, CA, USA) was implanted in the mid-body of the saphenous vein graft (SVG)-RCA (Figure 1C) whereas a XIENCE PRIME™ 3.0×23 mm stent (Abbott Vascular) was implanted in the mid-body of the SVG-OM (Figure 1D). The final angiographic results were good and there was no in-lab complication. He presented three months later with atypical chest pain and underwent cardiac computed tomographic angiography (CCTA). Both bioresorbable vascular scaffold (BVS) and XIENCE PRIME stent were widely patent on CCTA (Figure 1E and Figure 1F). No blooming artefact was observed within the treated SVG-RCA segment with the BVS platinum markers clearly seen on CCTA.

Figure 1. A) Baseline angiography showing critical stenosis in mid-body of SVG-RCA. B) Baseline angiography showing critical stenosis in mid-body of SVG-OM. C) Final angiography of SVG-RCA (after successful deployment of Absorb). D) Final angiography of SVG-OM (after successful deployment of XIENCE stent). E) CCTA showing widely patent BVS in mid-body of SVG-RCA. No blooming artefact observed with the BVS platinum markers clearly seen (small arrowheads >>) on CCTA. F) CCTA showing widely patent XIENCE metallic stent in mid-body of SVG-OM.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Online data supplement

Moving image 1. Movie clip showing the appearance of BVS in the mid-body of the SVG-RCA on CCTA.

Moving image 2. Movie clip showing the appearance of XIENCE stent in the mid-body of the SVG-OM on CCTA.

Supplementary data

To read the full content of this article, please download the PDF.

Moving image 1.
Moving image 2.
Volume 9 Number 1
May 21, 2013
Volume 9 Number 1
View full issue


Key metrics

Suggested by Cory

IMAGE IN CARDIOLOGY

10.4244/EIJV11I1A14 May 19, 2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity
Azzalini L et al
free

IMAGE IN CARDIOLOGY

10.4244/EIJV10I12A253 Apr 20, 2015
Coronary perforation after bioresorbable vascular scaffold implantation
Gomez-Lara J et al
free
Trending articles
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
48.8

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
What type of percutaneous coronary intervention was performed, and what devices were used?
What were the angiographic and CCTA findings at the 3-month follow-up?
What were the advantages of using a bioresorbable vascular scaffold in this case?
What factors should be considered when choosing between a bioresorbable vascular scaffold and a metallic stent for the treatment of saphenous vein graft lesions?
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved